This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Pegfilgrastim vs. Filgrastim - Comparison of Mobilized Blood Stem Cells in Patients With Non Hodgkin-lymphoma

This study has been completed.
Information provided by (Responsible Party):
Prof. Dr. med. Wolfgang Bethge, University Hospital Tuebingen Identifier:
First received: March 20, 2006
Last updated: May 28, 2014
Last verified: December 2012
The purpose of this study is to compare the ability of pegfilgrastim vs. filgrastim to mobilize peripheral blood stem cells in patients with Non Hodgkin-lymphoma in an intraindividual study

Condition Intervention Phase
Non-Hodgkin Lymphoma Drug: pegfilgrastim Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pegfilgrastim Versus Filgrastim - Intraindividual Comparison of Quantity and Quality of Mobilized Peripheral Blood Stem Cells in Patients With Non Hodgkin-lymphoma

Resource links provided by NLM:

Further study details as provided by Prof. Dr. med. Wolfgang Bethge, University Hospital Tuebingen:

Primary Outcome Measures:
  • Hematopoietic recovery after autologous stem cell transplantation [ Time Frame: 1-3 weeks after transplantation, follow up every 3 months (up to 2 years) ]
    Two cycles of conventional chemotherapy are given. Starting one day after the first cycle, filgrastim (5ug/kg bodyweight daily subcutaneously) is routinely administered to support neutrophil recovery. One day after the second cycle, a single dose of pegfilgrastim (6mg) is given to support neutrophil recovery and stem cell collection. Hematopoietic recovery (blood count) is monitored daily after high-dose therapy and autologous stem cell transplantation. Follow up assessments are performed 3-monthly for late graft failure

Secondary Outcome Measures:
  • Intraindividual comparison of quantity/quality of circulating stem cells [ Time Frame: before and during 3 weeks after conventional chemotherapy ]
    Circulating stem cells are enumerated by flow cytometry and colony assays during filgrastim (intraindividual control) and pegfilgrastim-supported recovery from chemotherapy.

Enrollment: 14
Study Start Date: January 2006
Study Completion Date: December 2011
Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Pegfilgrastim
Pegfilgrastim for stem cell mobilization (single arm)
Drug: pegfilgrastim
Single dose (6mg) one day after chemotherapy
Other Name: Neulasta(tm)

Detailed Description:
Patients with Non Hodgkin-lymphoma undergoing stem cell mobilization for planned high-dose therapy will be treated with two cycles of chemotherapy (etoposide, ifosfamide, cisplatin, epirubicin), either followed by daily administration of filgrastim (first cycle) or pegfilgrastim (once after the second cycle). The number of circulating cluster of differentiation 34+ cells, colony-forming units and primitive progenitors will be analyzed at corresponding time points. Peripheral blood stem cells will be collected after the second cycle of chemotherapy by leukapheresis. After the second cycle, high-dose therapy with peripheral blood stem cell support will be administered (the protocol will be chosen according to the diagnosis, including total body irradiation-containing regimens).

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • histological diagnosis of non-Hodgkin lymphoma
  • planned high-dose therapy with autologous stem cell transplantation
  • WHO performance status 0-2
  • written consent

Exclusion Criteria:

  • allergy against (peg)filgrastim
  • life expectancy <3 months
  • other malignant diseases within the last 5 years
  • cardial insufficiency (>= New York Heart Association II°)
  • uncontrolled infection
  • pregnancy, lactation
  • central nervous system lymphoma
  • Karnofsky score <70%
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00306111

Dept. of Medicine 2, University of Tuebingen
Tuebingen, BW, Germany, 72076
Sponsors and Collaborators
University Hospital Tuebingen
Principal Investigator: Robert Mohle, MD University of Tuebingen, Dept. of Medicine 2
  More Information

Responsible Party: Prof. Dr. med. Wolfgang Bethge, Oberarzt, University Hospital Tuebingen Identifier: NCT00306111     History of Changes
Other Study ID Numbers: rpm_001
Study First Received: March 20, 2006
Last Updated: May 28, 2014

Keywords provided by Prof. Dr. med. Wolfgang Bethge, University Hospital Tuebingen:
stem cell transplantation
stem cell mobilization
high-dose therapy

Additional relevant MeSH terms:
Lymphoma, Non-Hodgkin
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs processed this record on September 18, 2017